151 related articles for article (PubMed ID: 35905257)
1. Molecular and clinical features of a potential immunotherapy target ELK3 in glioma.
Xu H; Zhang L; Gao J; Wang J; Wang Y; Xiao D; Chai S
Medicine (Baltimore); 2022 Jul; 101(30):e29544. PubMed ID: 35905257
[TBL] [Abstract][Full Text] [Related]
2. Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target.
Xu H; Chai S; Wang Y; Wang J; Xiao D; Li J; Xiong N
CNS Neurosci Ther; 2020 Aug; 26(8):804-814. PubMed ID: 32678519
[TBL] [Abstract][Full Text] [Related]
3.
Liu Z; Ren Z; Zhang C; Qian R; Wang H; Wang J; Zhang W; Liu B; Lian X; Wang Y; Guo Y; Gao Y
Front Oncol; 2021; 11():608748. PubMed ID: 34976781
[TBL] [Abstract][Full Text] [Related]
4. High expression of COPB2 predicts adverse outcomes: A potential therapeutic target for glioma.
Zhou Y; Wang X; Huang X; Li XD; Cheng K; Yu H; Zhou YJ; Lv P; Jiang XB
CNS Neurosci Ther; 2020 Mar; 26(3):309-318. PubMed ID: 31710183
[TBL] [Abstract][Full Text] [Related]
5. Deciphering the role of QPCTL in glioma progression and cancer immunotherapy.
Liu Y; Lu S; Sun Y; Wang F; Yu S; Chen X; Wu LL; Yang H; Shi Y; Zhao K
Front Immunol; 2023; 14():1166377. PubMed ID: 37063864
[TBL] [Abstract][Full Text] [Related]
6. CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma.
Jiang Y; Ji Q; Long X; Wang P; Tu Z; Zhang X; Zhu X; Huang K; Li J
Front Immunol; 2022; 13():810832. PubMed ID: 35265072
[TBL] [Abstract][Full Text] [Related]
7. CNN3 in glioma: The prognostic factor and a potential immunotherapeutic target.
Xu H; Chai SS; Lv P; Wang JJ
Medicine (Baltimore); 2021 Nov; 100(46):e27931. PubMed ID: 34797350
[TBL] [Abstract][Full Text] [Related]
8. ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy.
Cheng X; Liu Z; Liang W; Zhu Q; Wang C; Wang H; Zhang J; Li P; Gao Y
Int J Biochem Cell Biol; 2023 May; 158():106409. PubMed ID: 36997057
[TBL] [Abstract][Full Text] [Related]
9. [Expression characteristics and functional analysis of ELK3 in gastric cancer].
Zhou L; Wu Y; Xin L
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Aug; 41(9):1287-1295. PubMed ID: 34658341
[TBL] [Abstract][Full Text] [Related]
10. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
11. Transcription Factor ELK3 Promotes Stemness and Oxaliplatin Resistance of Glioma Cells by Regulating RNASEH2A.
Mei Y; Chen D; He S; Ye J; Luo M; Wu Q; Huang Y
Horm Metab Res; 2023 Feb; 55(2):149-155. PubMed ID: 36638810
[TBL] [Abstract][Full Text] [Related]
12. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
Li J; Zhang Y; Qu Z; Ding R; Yin X
Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
[TBL] [Abstract][Full Text] [Related]
13.
Qu S; Liu J; Wang H
Front Immunol; 2021; 12():648416. PubMed ID: 33889156
[TBL] [Abstract][Full Text] [Related]
14. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
15. Pyroptosis: a novel signature to predict prognosis and immunotherapy response in gliomas.
He G; Chen Z; Zhuo S; Tang J; Hao W; Yang K; Yang C
Hum Cell; 2022 Nov; 35(6):1976-1992. PubMed ID: 36129672
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of PIMREG in the prognosis and response to immune checkpoint blockade of glioma patients.
Zhu H; Hu X; Feng S; Gu L; Jian Z; Zou N; Xiong X
Front Immunol; 2022; 13():946692. PubMed ID: 35928818
[TBL] [Abstract][Full Text] [Related]
17. FCGR2B as a prognostic and immune microenvironmental marker for gliomas based on transcriptomic analysis.
Sun Z; Sun X; Yuan Y; Li H; Li X; Yao Z
Medicine (Baltimore); 2023 Sep; 102(37):e35084. PubMed ID: 37713871
[TBL] [Abstract][Full Text] [Related]
18. Identification of FABP7 as a Potential Biomarker for Predicting Prognosis and Antiangiogenic Drug Efficacy of Glioma.
Hou L; Zhou H; Wang Y; Liu J; Zhang D; Li Y; Xue X
Dis Markers; 2022; 2022():2091791. PubMed ID: 35783014
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of mRNA Expression RBBP8 or Its Methylation in Gliomas.
Liu Z; Cheng X; Lin S; Han Z; Jin H; Luan Z; Li P; Liang W; Qian R; Gao Y
Cell Mol Neurobiol; 2023 Jan; 43(1):409-422. PubMed ID: 35106666
[TBL] [Abstract][Full Text] [Related]
20. Novel prognostic biomarker TBC1D1 is associated with immunotherapy resistance in gliomas.
Song D; Yang Q; Li L; Wei Y; Zhang C; Du H; Ren G; Li H
Front Immunol; 2024; 15():1372113. PubMed ID: 38529286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
